ResultsIQ

ResultsIQ › Latest results › Tatva Chintan Pharma Chem Limited

Tatva Chintan Pharma Chem Limited Q4 FY26 earnings call summary

NSE: TATVA · BSE: 543321

Earnings call of 16 May 2026, summarised by AI from the filing.

Tatva Chintan reported Q4 FY26 revenue of ₹1,341 mn, up 24% year-on-year, and reiterates FY27 guidance of 25% revenue growth and 20% to 22% EBITDA margin.

Key takeaways

  1. FY27 guidance Management reiterates 25% revenue growth and 20% to 22% EBITDA margin for FY27.
  2. Electrolyte salts Segment revenue jumped to ₹131 mn in Q4 FY26, up 865% quarter-on-quarter.
  3. Growth drivers Pharma commercialization, SDA Euro 7 transition, and electrolyte salts ramp-up drive growth.
  4. Raw material risk Amine prices up 30% to 40% due to geopolitical issues, though mostly passed on to customers.

Original filing on BSE

Tatva Chintan Pharma Chem Limited Q1 FY27 results

As filed: Revenue ₹167 cr (+43% year on year), EBITDA ₹32.3 cr (+90% year on year), PAT ₹16.0 cr (+128% year on year), EBITDA margin 19.3% (+480 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹134 cr (+24% year on year), EBITDA ₹28.1 cr (+252% year on year), PAT ₹10.3 cr (+300% year on year), EBITDA margin 21.0% (+1,000 bps). Score 84 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 1000 bps year on year. Tax rate 38%. Profit fell 32% from last quarter. Revenue rose ₹26.1 cr on a year ago, more than the ₹10.0 cr it added the year before. Share price after the results: −10.4% in 30 days (Nifty 500: +1.6%).
  • Q3 FY26: Revenue ₹131 cr (+53% year on year), EBITDA ₹25.5 cr (+264% year on year), PAT ₹15.2 cr, EBITDA margin 19.4% (+1,000 bps). Score 90 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate 14%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −8.8% in 30 days (Nifty 500: +2.5%).
  • Q2 FY26: Revenue ₹124 cr (+49% year on year), EBITDA ₹23.0 cr (+283% year on year), PAT ₹10.0 cr, EBITDA margin 18.6% (+1,000 bps). Score 100 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +2.4% in 28 days (Nifty 500: +0.9%).
  • Q1 FY26: Revenue ₹117 cr (+11% year on year), EBITDA ₹17.0 cr (+31% year on year), PAT ₹7.0 cr (+40% year on year), EBITDA margin 14.5% (+215 bps). Score 77 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 215 bps year on year. Share price after the results: +9.0% in 29 days (Nifty 500: −1.3%).
  • Q4 FY25: Revenue ₹108 cr (+10% year on year), EBITDA ₹8.0 cr (−47% year on year), PAT ₹1.0 cr (−90% year on year), EBITDA margin 7.4% (−790 bps). Score 28 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 790 bps year on year. Other income 50% of PBT. Tax rate 50%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +22.8% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹86.0 cr (+2% year on year), EBITDA ₹7.0 cr (−36% year on year), PAT ₹0.0 cr (−100% year on year), EBITDA margin 8.1% (−496 bps). Score 20 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 496 bps year on year.
  • Q2 FY25: Revenue ₹83.0 cr (−14% year on year), EBITDA ₹6.0 cr (−70% year on year), PAT −₹1.0 cr (−113% year on year), EBITDA margin 7.2% (−1,000 bps). Score 2 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 21% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Tatva Chintan Pharma Chem Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.